Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus STERANE.
DECADRON W/ XYLOCAINE vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
100 mg orally every 12 hours
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Corticosteroid